Summary by Futu AI
On June 26, 2024, BeiGene Medicine B submitted a biological product license application (BLA) for batolimumab (HBM9161) to the National Medical Products Administration (NMPA) of China again. Batolimumab is a fully human monoclonal antibody that specifically binds and inhibits neonatal FcRn, which is expected to become a new treatment for a variety of autoimmune diseases in the Greater China region. The company reminds shareholders and potential investors that it is not guaranteed that the drug will be successfully marketed and should proceed with caution. The announcement also contains forward-looking statements, but the company does not guarantee to update these statements regularly and points out that actual results may differ from expectations for various reasons.